Certified by Founder Lodge
Catalio Capital Management
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $89,000,000
42 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Managem
| Company | Date | Round | Raised |
|---|---|---|---|
 Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
 Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
 Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
 xilis |
July, 13 ,2022 | Series A | $89,000,000 |
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 NextPoint Therapeutics, Inc. |
February, 15 ,2024 | Series B | $42,500,000 |
 Ensoma |
February, 06 ,2023 | Series B | $85,000,000 |
 Georgiamune Inc. |
August, 10 ,2023 | Series A | $75,000,000 |
 Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
 Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
 Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
| Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
 PinkDx, Inc. |
April, 26 ,2024 | Series A | $40,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
 NOETIK |
September, 08 ,2023 | Seed | $14,000,000 |
| NextPoint Therapeutics, Inc. |
February, 15 ,2024 | Series B | $42,500,000 |
 INSIGHTEC |
June, 20 ,2024 | Unknown | $150,000,000 |
| Georgiamune Inc. |
August, 10 ,2023 | Series A | $75,000,000 |
| Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| PinkDx, Inc. |
April, 26 ,2024 | Series A | $40,000,000 |
| Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
| NextPoint Therapeutics, Inc. |
February, 15 ,2024 | Series B | $42,500,000 |
| NOETIK |
September, 08 ,2023 | Seed | $14,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| INSIGHTEC |
June, 20 ,2024 | Unknown | $150,000,000 |
| PinkDx, Inc. |
April, 26 ,2024 | Series A | $40,000,000 |
| Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
| INSIGHTEC |
June, 20 ,2024 | Unknown | $150,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Perceive Biotherapeutics, Inc. |
February, 20 ,2025 | Series A | $15,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
| NextPoint Therapeutics, Inc. |
February, 15 ,2024 | Series B | $42,500,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| PinkDx, Inc. |
April, 26 ,2024 | Series A | $40,000,000 |
| INSIGHTEC |
June, 20 ,2024 | Unknown | $150,000,000 |
| Perceive Biotherapeutics, Inc. |
February, 20 ,2025 | Series A | $15,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
